

PORZIO

Bromberg & Newman



Puerto Rico Pharmaceutical Summit Agenda

8:00 am

Registration

8:45am

Welcome Remarks & Introduction of Keynote Speaker

Vito A. Gagliardi, Jr. | Managing Principal | Porzio, Bromberg & Newman, P.C.
Luis G. Rivera-Marín | Of Counsel | Porzio, Bromberg & Newman (PR), LLC

9:00 am

Keynote Speaker

The Honorable, Pedro Pierluisi | Governor of Puerto Rico

9:30 am

State of the Pharmaceutical Industry in Puerto Rico: Economic Development / Onshoring

Yandia Pérez | Executive Director | PRMA
Ivan Roman | Consultant | Puerto Rico Pharmaceutical Industry Association
Manuel Cidre Miranda | Secretary of the Department of Economic Development and Commerce (DEDC)
Francisco E. Colón-Ramírez | Of Counsel | Porzio, Bromberg & Newman, P.C.

10:15 am

Break

10:30 am

FDA Perspective: Brief Overview of Steps for Approval of Drugs for Use in the United States; Importation of Approved Drugs from Puerto Rico; and Selling Drug Products into Puerto Rico

Karla Palmer | Partner | Hyman Phelps & McNamara
Dara Levy | Director | Hyman Phelps & McNamara
Matthew Ludowig | GC | Empower Pharmacy

11:15 am

Puerto Rico's Play in Biopharma Innovation

Ella Woger-Nieves | CEO | Invest Puerto Rico
Mr. Robert Salcedo | CEO | Ocyonbio
Mrs. Lucy Crespo | CEO | Puerto Rico Science, Technology & Research Trust
Mr. Ivan Lugo | Executive Director | Induniv

12:00 pm

Understanding Industry Incentives: Puerto Rico's Position as the Most Competitive Jurisdiction for Pharma and Life Sciences

Ana Izquierdo-Henn | Director of Incentives & Legal Counsel | DECA Analytics

Colton Wandke, CAIA | Co-Founder & Partner | DECA Analytics

Aurelio Fuentes | DECA Analytics

Will Rosellini | President | CytImmune Therapeutics

Dr. Satish Iduru | Founder | Learis KN Life Sciences

Humberto Mercader | Deputy Secretary for Strategic Initiatives | Puerto Rico Department of Economic Development and Commerce

Carlos Fontan | Director | Puerto Rico Office of Incentives

12:45 pm

Networking Lunch

1:30 pm

Washington Policy and the Inflation Reduction Act: How It Changed the Pharmaceutical Industry Forever

Paul Edattel | Principal | Todd Strategy Group

Juan L. Negron | Director of Public Policy | Merck

Sean Keveney | Deputy General Counsel | US Department of Health and Human Services

Stuart Portman | Senior Health Policy Advisor | US Senate Committee on Finance

2:15 pm

Power in Puerto Rico and the Continued Quest for Reliable Renewable Energy: New Opportunities & the Best Path Forward

Joseph A. Paparo | Principal | Porzio, Bromberg & Newman, P.C.

Carmen Andrade | Principal | Porzio, Bromberg & Newman, P.C.

Javier Rúa | Chief Public Policy Officer | Puerto Rico Solar Energy and Storage Association JB Cuartas, IEM

Carlos Fernandez Lugo | Chair, Environmental, Energy and Land Use | McConnell Valdes, LLC

Ryan G. Christiansen CCIM | President and Founder | Christiansen Commercial Real Estate

3:00 pm

Break

3:15 pm

2023 Tax Incentives & Recent Developments

Isabel Hernández | CPA - Partner | Kevane Grant Thornton, LLP

Raquel Rivera | Attorney | Porzio, Bromberg & Newman, P.C.

3:45 pm

Navigating the Latest PBM Trends: Insights and Strategies for Success

Jonathan Levitt | Founding Partner | Frier Levitt

4:30 pm

Pharmaceutical Licensing and Supply Chain: Navigating and Understanding Ever Changing Regulations to Avoid Distribution Disruptions

Frank Fazio | Senior Vice President, Distribution and Licensing Services | Porzio Compliance Services

5:15 pm

Questions and Closing Remarks

Vito A. Gagliardi, Jr. | Managing Principal | Porzio, Bromberg & Newman, P.C.

5:30 pm

Reception

Event Overview

With global supply chains continuing to face massive disruptions, the need to create infrastructure and economic incentives for pharmaceutical companies doing business in Puerto Rico is apparent.

Porzio has partnered with industry-leading subject matter experts for a one day conference. The 2023 Puerto Rico Pharmaceutical Summit will bring together thought leaders, business executives, government representatives, and policy influencers who will provide exclusive insights on why pharmaceutical companies must consider Puerto Rico for their business operations and further the conversation on what must be done on the island to support this critical industry.